AtriCure Announces Investor Update Webcast on May 8, 2020 in Conjunction with the 41st Annual Heart Rhythm Society (HRS) Virt...
April 30 2020 - 8:30AM
Business Wire
AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in treatments
for atrial fibrillation (Afib) and left atrial appendage (LAA)
management, today announced that the company will host an analyst
and institutional investor update webcast at 1:00 p.m. Eastern Time
on Friday, May 8, 2020, to coincide with the 41st Annual Heart
Rhythm Scientific Sessions.
The webcast will include remarks from the Principal Investigator
of the CONVERGE IDE trial as well an interactive question and
answer session with a panel of clinicians. Interested parties may
access a live audio webcast of the presentation by visiting the
“Investors” section of the company’s website at
https://ir.atricure.com. A replay of the webcast will be available
following the presentation.
About AtriCure
AtriCure, Inc. provides innovative technologies for the
treatment of Afib and related conditions. Afib affects more than 33
million people worldwide. Electrophysiologists and cardiothoracic
surgeons around the globe use AtriCure technologies for the
treatment of Afib and reduction of Afib related complications.
AtriCure’s Isolator® Synergy™ Ablation System is the first and only
medical device to receive FDA approval for the treatment of
persistent Afib. AtriCure’s AtriClip® Left Atrial Appendage
Exclusion System products are the most widely sold LAA management
devices worldwide. For more information, visit AtriCure.com or
follow us on Twitter @AtriCure.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20200430005052/en/
Andy Wade AtriCure, Inc. Senior Vice President and Chief
Financial Officer (513) 755-4564 awade@atricure.com
Lynn Pieper Lewis Gilmartin Group Investor Relations (415)
937-5402 lynn@gilmartinir.com
AtriCure (NASDAQ:ATRC)
Historical Stock Chart
From Aug 2024 to Sep 2024
AtriCure (NASDAQ:ATRC)
Historical Stock Chart
From Sep 2023 to Sep 2024